Patents by Inventor Kuiwang Wu

Kuiwang Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDE4 INHIBITOR COMPOUND AND MEDICAL USE THEREOF
    Publication number: 20230141101
    Abstract: A class of PDE4 inhibitor compounds, and an isomer, solvate, deuterated derivative, or pharmaceutically acceptable salt thereof. A drug that comprises the compound, isomer, solvate, deuterated derivative, and pharmaceutically acceptable salt thereof, and a use thereof in preparing a drug for treating diseases related to PDE4 inhibition, such as autoimmune diseases and cancer.
    Type: Application
    Filed: February 22, 2021
    Publication date: May 11, 2023
    Applicant: Suzhou Longbotai Pharmaceuticals Co., Ltd.
    Inventors: Shuxin Li, Hengying Yang, Sheng Kuang, Sifan She, Kuiwang Wu, Shiwei Li
  • Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof
    Patent number: 11414413
    Abstract: Disclosed are a heterocyclic derivative as a JAK inhibitor, and salts thereof, wherein the definitions of (II), (III) and R are described in detail in the specification. In addition, also disclosed are a medicine including the compound and salts thereof as an active ingredient, and the use thereof in the preparation of a medicine for treating JAK-related target diseases, such as immune system diseases, rheumatoid arthritis and tumors.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: August 16, 2022
    Assignee: Suzhou Longbiotech Pharmaceuticals Co., Ltd.
    Inventors: Hengying Yang, Sheng Kuang, Shiwei Li, Kuiwang Wu, Shuxin Li
  • Compound as selective JAK inhibitor, and salt and therapeutic use thereof
    Patent number: 11279699
    Abstract: Disclosed are a compound as a selective JAK inhibitor, and an isomer, a solvate or a pharmaceutically acceptable salt thereof, wherein: the definitions of (A), R, R1 and n are described in detail in the specification. In addition, also disclosed are a medicament including the compound and salts thereof as an active ingredient, and the use thereof in the preparation of a medicament for treating JAK-related target diseases, such as immune system diseases, rheumatoid arthritis and tumors.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: March 22, 2022
    Assignee: Suzhou Longbiotech Pharmaceuticals Co., Ltd.
    Inventors: Hengying Yang, Sheng Kuang, Shiwei Li, Kuiwang Wu, Shuxin Li